Clinical lipid control success rate before and after percutaneous coronary intervention in iran; a single center
Seyed Kianoosh Hosseini1, Maryam Tahvildari2, Mohammad Javad Alemzadeh Ansari1
1Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, IR Iran.
Insights
High cholesterol is a risk factor for cardiovascular disease (CVD). After percutaneous coronary intervention (PCI), lipid control improved, but dyslipidemia persisted in many patients, necessitating further research.
Area of Science:
- Cardiology
- Lipidology
- Interventional Cardiology
Background:
- High cholesterol levels are a recognized independent risk factor for cardiovascular disease (CVD).
- Effective management of dyslipidemia is crucial for patients with coronary artery disease (CAD).
Purpose of the Study:
- To evaluate the success rate of lipid control in patients following percutaneous coronary intervention (PCI).
- To assess lipid profile changes and dyslipidemia prevalence at a 9-month follow-up after PCI.
Main Methods:
- A cohort of 195 patients (mean age 57.8 years, 67.7% male) who underwent PCI were studied.
- Serum lipid profiles (TC, LDL-C, HDL-C, TG, non-HDL-C) were measured pre-PCI and at 9-month follow-up.
- Dyslipidemia was defined using established criteria, and patients received atorvastatin (20-40 mg/day) during follow-up.
Main Results:
- At 9 months post-PCI, a significant increase in the prevalence of low total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) was observed.
- Specifically, LDL-C prevalence increased from 47.2% to 65.6% (p < 0.001), and non-HDL-C from 40.0% to 63.1% (p < 0.001).
- No significant changes were noted in high HDL-C or low triglyceride prevalence, but dyslipidemia remained prevalent.
Conclusions:
- Current lipid-lowering treatments significantly increased the prevalence of low TC, LDL-C, and non-HDL-C post-PCI.
- Despite treatment, dyslipidemia persisted in a substantial proportion of patients, indicating a need for optimized therapeutic strategies.
- Further investigation is warranted to understand the long-term outcomes related to serum lipids and refine dyslipidemia management post-PCI.
Background:
High cholesterol levels have long been considered an independent risk factor for cardiovascular disease (CVD).
Objective:
Controlling risk factors such as dyslipidemia in patients with coronary artery disease is necessary. We aimed to evaluate the success rate of lipid control, during 9 months follow-up after percutaneous coronary intervention (PCI).
Patients And Methods:
A total of 195 patients (67.7% men, mean age = 57.8 ± 9.4 years) who underwent PCI in Tehran Heart Center were included. Serum lipid profiles were measured in all the patients before PCI and at 9-month follow-up. Dyslipidemia was defined as serum levels of LDL-C ≥ 100 or TG ≥ 150 or TC ≥ 200 or HDL-C ≤ 40 mg/dl in the men and ≤ 50 mg/dl or less in the women, or non-HDL-C ≥ 130 mg/dl with or without the consumption of lipid-lowering agents. During follow up, all patients were given atorvastatin 20-40 mg/day.
Results:
Overall, 26.2% had diabetes mellitus, 42.6% had hypertension, and 34.9% were smokers. Dyslipidemia was more common in the women. At 9-month follow-up, there was no significant changes in terms of the prevalence of high HDL-C or low TG in patients; however, a significant increase was seen in the prevalence low TC in patients (63.6% vs. 80.5%; p value < 0.001), LDL-C (47.2% vs. 65.6%; p value < 0.001), and non-HDL-C (40.0% vs. 63.1%; p value < 0.001).
Conclusions:
Although by current treatments, the prevalence of patients with low TC, LDL-C and non-HDL-C has significantly increased; dyslipidemia persisted in a considerable proportion of patients. These results necessitate further investigations into the relationship between high serum lipids and long-term outcome of patients after PCI as well as further evaluations of the dyslipidemia treatment strategies.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care